Grover G J, Sleph P G, Dzwonczyk S, Wang P, Fung W, Tobias D, Cushman D W
Department of Pharmacology, Squibb Institute for Medical Research, Princeton, New Jersey.
J Pharmacol Exp Ther. 1991 Jun;257(3):919-29.
We determined the relationship between cardiac angiotensin-converting enzyme (ACE) inhibition and anti-ischemic efficacy of several structurally different ACE inhibitors or their prodrug esters perfused through the isolated rat heart. Seven ACE inhibitors inhibited cardiac ACE to varying degrees due to differences in uptake during perfusion through nonischemic rat hearts. Zofenopril-sulfhydryl and fosinoprilic acid were the most effective of the free inhibitors. Among the prodrugs, zofenopril and S-benzoylcaptopril, hydrolyzed rapidly by cardiac esterase, were more effective than their component ACE-inhibitors, whereas fosinopril, ramipril and enalapril were poorly active. For studies in ischemic rat hearts, vehicle or drug treatment was initiated 10 min before a 25-min period of global ischemia and during a 30-min reperfusion period. Of five unesterified ACE inhibitors studied for anti-ischemic activity, only captopril and zofenopril-sulfhydryl were found to improve postischemic contractile function and reduce cell death in the isolated rat hearts. Fosinoprilic acid, ramiprilat and enalaprilat were not cardioprotective at high perfusion concentrations, despite the fact that nearly complete inhibition of cardiac ACE was achieved with all of the compounds studied. The S-benzoyl prodrugs of zofenopril-sulfhydryl and captopril were at least as potent as their component ACE inhibitors in reducing ischemic-reperfusion damage in the same model. Neither zofenopril nor captopril, however, had any effect on coronary flow before or after ischemia. Thus, it appears that the cardioprotective effects of zofenopril and captopril are independent of cardiac ACE inhibition or, at least, that ACE inhibition alone is not sufficient. Both captopril and zofenopril are sulfhydryl-containing compounds whereas the inactive compounds are not; and, thus, this group appears to be important in mediating their cardioprotective actions.
我们确定了心脏血管紧张素转换酶(ACE)抑制与几种结构不同的ACE抑制剂或其前药酯经离体大鼠心脏灌注后的抗缺血疗效之间的关系。七种ACE抑制剂由于在非缺血大鼠心脏灌注期间摄取存在差异,对心脏ACE的抑制程度各不相同。佐芬普利巯基和福辛普利酸是游离抑制剂中最有效的。在前药中,被心脏酯酶快速水解的佐芬普利和S-苯甲酰卡托普利比其组成的ACE抑制剂更有效,而福辛普利、雷米普利和依那普利活性较差。对于缺血大鼠心脏的研究,在25分钟全心缺血期前10分钟以及30分钟再灌注期开始给予溶剂或药物治疗。在研究抗缺血活性的五种未酯化ACE抑制剂中,仅发现卡托普利和佐芬普利巯基可改善离体大鼠心脏缺血后的收缩功能并减少细胞死亡。尽管在所研究的所有化合物均几乎完全抑制心脏ACE,但高灌注浓度下福辛普利酸、雷米普利拉和依那普利拉并无心脏保护作用。佐芬普利巯基和卡托普利的S-苯甲酰前药在同一模型中减少缺血再灌注损伤方面至少与其组成的ACE抑制剂一样有效。然而,佐芬普利和卡托普利对缺血前后的冠脉血流均无影响。因此,似乎佐芬普利和卡托普利的心脏保护作用独立于心脏ACE抑制,或者至少单独的ACE抑制是不够的。卡托普利和佐芬普利均为含巯基化合物,而无活性的化合物则不是;因此,这一组似乎在介导其心脏保护作用中很重要。